#Germany #Bad Homburg #Fresenius Medical #Hemodiafiltration #BEACON-US

Fresenius Medical Care Launches BEACON-US to Enhance Patient Care in Dialysis

Fresenius Medical Care (FME), a frontrunner in products and services for those battling kidney disease, has taken a significant step forward in patient care by launching a new research initiative known as BEACON-US. This initiative aims to expand the understanding and effectiveness of high-volume hemodiafiltration (HVHDF) therapy for dialysis patients across the United States.

Understanding BEACON-US

The BEACON-US project stands for Benefits, Effectiveness, And Convective Outcomes in Nephrology – United States. It serves as a comprehensive research endeavor that seeks to gather real-world evidence concerning how HVHDF therapy performs in routine clinical settings for diverse patient demographics. By building on nearly two decades of experience and research from over 90 countries, FME aims to transform kidney care standards in the U.S.

Helen Giza, CEO of Fresenius Medical Care, emphasized the importance of this initiative, stating, “High-volume hemodiafiltration has the potential to transform the standard of kidney care in the United States and is a key part of our FME Reignite strategy as we accelerate growth and innovation.”

Positive Early Findings

Initial results from the BEACON-US initiative have shown promising trends. Patients receiving HVHDF report feeling better during and after their dialysis treatments. For example, data indicates that muscle cramps occurred 40% less frequently among these patients. With the innovative AutoSub plus technology, over 70% of treatments have successfully met the HVHDF target of at least 23 liters of convective volume per session. These emerging U.S. data correlate with strong international evidence, including findings from the CONVINCE trial, which have established HVHDF as a preferred standard of care in many countries around the globe.

Evidence supporting HVHDF is compelling; it is associated with reduced hospitalization rates, enhanced treatment tolerability, fewer instances of low blood pressure during dialysis, and improved survival metrics. As the prevalence of kidney disease continues to rise, providing broader access to effective therapies becomes increasingly crucial.

Real-World Evidence and Ongoing Benefits

The BEACON-US initiative is actively tracking clinical performance metrics, showing that HVHDF therapy supports enhanced dialysis adequacy targets (Kt/V) while delivering higher convective volumes without extending treatment durations or increasing water usage. Clinicians have highlighted that the intelligent automation offered by this technology simplifies operational workflows, optimizing both clinic resources and creating a quieter, more comfortable environment for patients and healthcare providers alike.

HVHDF uniquely combines diffusion, a core mechanism utilized in traditional hemodialysis, with enhanced convection to effectively remove a wider array of waste materials from the bloodstream. With a targeted convective volume of at least 23 liters per session, HVHDF underscores the importance of precise clinical monitoring to achieve intended therapeutic results.

Building on a Strong Evidence Base

The foundation of BEACON-US is strengthened by a substantial body of international research. Notably, large-scale studies indicate that patients commencing dialysis with HDF are at a lower risk of mortality compared to their counterparts on conventional hemodialysis. Moreover, research indicates that patients undergoing HVHDF experienced fewer hospitalization days and thus can spend more time outside hospitals, ultimately enhancing their quality of life.

Fresenius Medical Care has successfully integrated a blend of technological innovation with deep clinical research capabilities, enabling the company to evaluate the real-world impact of new therapies comprehensively. This integration is vital in refining patient care for individuals living with kidney failure.

In summary, Fresenius Medical Care’s BEACON-US initiative marks a significant advancement in understanding high-volume hemodiafiltration therapy and its benefits for U.S. dialysis patients. As the program progresses, it holds the potential to reshape kidney disease management, promising improved outcomes for patients and healthcare systems alike.